Actinium Pharmaceuticals, Inc. (ATNM) — SEC Filings
Actinium Pharmaceuticals, Inc. (ATNM) — 18 SEC filings. Latest: 10-K (Mar 30, 2026). Includes 6 10-Q, 4 SC 13G/A, 3 10-K.
View Actinium Pharmaceuticals, Inc. on SEC EDGAR
Overview
Actinium Pharmaceuticals, Inc. (ATNM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 30, 2026: Actinium Pharmaceuticals, Inc. (ATNM) is a clinical-stage biopharmaceutical company focused on targeted radiotherapies, reporting a market value of voting stock held by nonaffiliates of $43,663,089 as of June 30, 2025. The company is pioneering a biology-driven approach with a pipeline including two
Sentiment Summary
Across 18 filings, the sentiment breakdown is: 1 bullish, 14 neutral, 3 mixed. The dominant filing sentiment for Actinium Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Actinium Pharmaceuticals, Inc. (ATNM) has filed 3 10-K, 3 8-K, 6 10-Q, 1 DEF 14A, 4 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (18)
Risk Profile
Risk Assessment: Of ATNM's 14 recent filings, 2 were flagged as high-risk, 5 as medium-risk, and 7 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Sandesh Seth
- Ajit Shetty
- June S. Almenoff
- Gary Siegel
Industry Context
The radiopharmaceutical market is experiencing rapid growth and validation, evidenced by blockbuster sales of drugs like Pluvicto ($2 billion in 2025) and significant M&A activity ($17 billion from 2013-2023). This growth is attracting substantial strategic investments and licensing transactions, highlighting the industry's potential. However, the space is becoming increasingly competitive, with many companies focusing on a limited number of targets.
Top Tags
pharmaceuticals (5) · Biotechnology (4) · 10-Q (4) · Oncology (3) · quarterly-report (3) · Radiopharmaceuticals (2) · Clinical Stage (2) · SEC Filing (2) · 10-K (2) · Targeted Therapy (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of voting stock held by nonaffiliates | $43,663,089 | as of June 30, 2025, indicating company size |
| Shares of common stock outstanding | 31,374,994 | as of March 30, 2026 |
| Pluvicto sales | $2 billion | in 2025, demonstrating market potential for radiopharmaceuticals |
| Pluvicto forecast peak sales | $5 billion | by Novartis, highlighting the blockbuster potential |
| High-value M&A in radiopharmaceuticals | $17 billion | from 2013 to 2023, showing industry consolidation and interest |
| Strategic investments and licensing transactions | $8 billion | since 2024, targeting novel radiotherapy assets |
| Issued patents and pending patent applications | 250 | comprising Actinium's intellectual property portfolio |
| Patients treated | 500 | in Actinium's clinical trials to date, demonstrating clinical experience |
| Expected commissioning of manufacturing facility | 2H:2026 | indicating progress in vertical integration |
| Superiority of ATNM-400 | 3-5 fold | over leading approved therapies in EGFR-mutant NSCLC models |
| Net Loss (Q3 2025) | $5.131M | 55.7% decrease from $11.568M in Q3 2024 |
| Net Loss (9M 2025) | $27.947M | 11.5% decrease from $31.591M in 9M 2024 |
| Total Revenue (9M 2025) | $90K | Increase from $0 in 9M 2024, primarily from grant revenue |
| R&D Expenses (Q3 2025) | $4.248M | 56.5% decrease from $9.774M in Q3 2024 |
| G&A Expenses (Q3 2025) | $1.534M | 45.7% decrease from $2.827M in Q3 2024 |
Forward-Looking Statements
- {"claim":"Bigger Capital Fund, LP will maintain a significant stake in Actinium Pharmaceuticals, Inc. for the foreseeable future.","entity":"Bigger Capital Fund, LP","targetDate":"2025-12-31","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Actinium Pharmaceuticals, Inc. (ATNM)?
Actinium Pharmaceuticals, Inc. has 18 recent SEC filings from Jan 2024 to Mar 2026, including 6 10-Q, 4 SC 13G/A, 3 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ATNM filings?
Across 18 filings, the sentiment breakdown is: 1 bullish, 14 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Actinium Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Actinium Pharmaceuticals, Inc. (ATNM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Actinium Pharmaceuticals, Inc.?
Key financial highlights from Actinium Pharmaceuticals, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ATNM?
The investment thesis for ATNM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Actinium Pharmaceuticals, Inc.?
Key executives identified across Actinium Pharmaceuticals, Inc.'s filings include Sandesh Seth, Ajit Shetty, June S. Almenoff, Gary Siegel.
What are the main risk factors for Actinium Pharmaceuticals, Inc. stock?
Of ATNM's 14 assessed filings, 2 were flagged high-risk, 5 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Actinium Pharmaceuticals, Inc.?
Recent forward-looking statements from Actinium Pharmaceuticals, Inc. include guidance on {"claim":"Bigger Capital Fund, LP will maintain a significant stake in Actinium Pharmaceuticals, Inc. for the foreseeabl.